



T-CALM

Tremor-CAv3 Modulation Study



Have you been diagnosed with essential tremor?

Learn about a new clinical trial for essential tremor (ET)

The T-CALM study will evaluate whether investigational oral drug CX-8998 reduces the severity of tremors by reducing abnormal activity in certain regions of the brain.

People with essential tremor will participate in the study for 5 weeks. Participants in the study will be randomly assigned to one of two groups – half will receive the study drug and the other half will be given a placebo (sugar pill). In order to scientifically assess the effects of the drug, neither the participants nor the clinical team will know during the study what group each participant is in.

Eligibility requirements include:

- Men and women (not pregnant or breastfeeding) 18 to 75 years-of-age
- Diagnosis prior to age 65 of essential tremor affecting both hands and arms
- No previous brain surgery, focused ultrasound or deep brain stimulation for tremor
- No known history of other causes of tremor, such as Parkinson's disease, hyperthyroidism, multiple sclerosis, or head trauma or brain disease in the 3 months before the tremor began

You may be eligible for the study even if you are already taking one medication for tremor.
(However, people using Primidone will be asked to discontinue it prior to starting the study.)

The safety and efficacy of CX-8998 for treatment of essential tremor have not been established

Participation in the study is free

If you are interested in participating in the study, please call
201- 822-5608 (201-TCALM08) or send an email to
ettrial@cavionpharma.com

**Cavion**

Study Sponsor

www.cavionpharma.com